Merck Poised for Lucrative Acquisition of Cidara Therapeutics

Post by : Bianca Suleiman

Merck is nearing the completion of a significant acquisition, moving towards a deal to purchase the biotechnology firm Cidara Therapeutics at a premium above its estimated $3.3 billion market capitalization, as reported on Thursday. Sources familiar with the negotiations informed the Financial Times that the contract might be revealed as soon as Friday if discussions remain positive.

The bidding was competitive until late Thursday, with one other pharmaceutical player still vying for the acquisition before Cidara leaned toward Merck’s offer. Although the precise price remains undisclosed, it's anticipated that the agreement will involve upfront cash alongside milestone payments linked to the progress of clinical developments. This payment structure is often seen in biotech acquisitions where drug candidates are still evolving.

Cidara has attracted considerable attention within the industry lately. In October, the U.S. Food and Drug Administration awarded “breakthrough therapy” status to CD388, Cidara’s innovative antiviral intended to avert influenza A and B in high-risk populations. This status is designed to speed up the development and regulatory review of treatments addressing significant healthcare challenges.

While Cidara opted not to comment on the ongoing negotiations, Merck has yet to respond promptly. If the acquisition is finalized, it will represent a significant achievement for Merck, enhancing its offerings in infectious disease prevention and reinforcing its foothold in the competitive biotech sector.